The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
Abstract
PURPOSE: To determine risk factors for the development of second primary cancers during long-term follow-up of patients with Hodgkin's disease (HD). PATIENTS AND METHODS: We assessed the risk of second cancers (SCs) in 1939 HD patients, who were admitted to the Netherlands Cancer Institute (NKI; Amsterdam) or the Dr Daniel den Hoed Cancer Center (DDHK; Rotterdam) between 1966 and 1986. For 97% of the cohort, we obtained a medical status up to at least January 1989. The median follow-up duration of the patients was 9.2 years; for 17% of the patients, follow-up was longer than 15 years. For more than 98% of all second tumors, the diagnosis was confirmed through a pathology report. RESULTS: In all, 146 patients developed a SC, compared with 41.9 cases expected on the basis of incidence rates in the general population (relative risk [RR], 3.5; 95% confidence interval [CI], 2.9 to 4.1). The mean 20-year actuarial risk of all SCs was 20% (95% CI, 17% to 24%). Significantly increased RRs were observed for leukemia (RR, 34.7; 95% CI, 23.6 to 49.3), non-Hodgkin's lymphoma (NHL) (RR, 20.6; 95% CI, 13.1 to 30.9), lung cancer (RR, 3.7; 95% CI, 2.5 to 5.3), all gastrointestinal cancers combined (RR, 2.0; 95% CI, 1.2 to 3.1), all urogenital cancers combined (RR, 2.4; 95% CI, 1.4 to 3.7), melanoma (RR, 4.9; 95% CI, 1.6 to 11.3), and soft tissue sarcoma (RR, 8.8; 95% CI, 1.8 to 25.8). As compared with the general population, the cohort experienced an excess of 63 cancer cases per 10,000 person-years. Cox-model analysis indicated the following as significant risk factors for developing leukemia: first-year treatment with chemotherapy (CT), follow-up treatment with CT, age at diagnosis of HD greater than 40 years, splenectomy, and advanced stage. Patients treated with CT in the 1980s had a substantially lower risk of leukemia than patients treated in the 1970s (10-year actuarial risks of 2.1% and 6.4%, respectively; P = .07). Significant risk factors for NHL were older age, male sex, and combined modality treatment as compared with either modality alone. Risk of lung cancer was strongly related to radiotherapy (RT), while an additional role of CT could not be demonstrated. After more than 15 years of follow-up, women treated with mantle-field irradiation before age 20 years had a greater than forty-fold increased risk of breast cancer (P < .001). CONCLUSION: While the long-term consequences of HD treatment as administered in the 1960s and 1970s are still evolving, it is promising that patients who received the new treatment regimens introduced in the 1980s have a much lower leukemia risk than patients treated in earlier years. Beginning 10 years after initial RT, the follow-up program of women who received mantle-field irradiation before age 30 years should routinely include breast palpation and yearly mammography.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
Zuckerman, A. J. (1995) · Journal of Clinical Pathology · doi:10.1136/jcp.48.7.691-a · Cited by 8,728
Cancer Incidence in Five Continents
(1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,501
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
BMPD statistical software manual
Dixon, W. (1988) · University of California Press eBooks · Cited by 2,536
Biometrika Tables for Statisticians
Savage, I. R., Pearson, E. S., & Hartley, H. O. (1967) · Mathematics of Computation · doi:10.2307/2004190 · Cited by 1,435
Huerta, G. T., & Villasana, J. E. M. (1988) · PubMed · Cited by 804
Risk of Second Cancers after Treatment for Hodgkin's Disease
Tucker, M. A., Coleman, C. N., Cox, R. S., Varghese, A., & Rosenberg, S. A. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801143180203 · Cited by 718
Breast Cancer After Treatment of Hodgkin's Disease
Hancock, S. L., Tucker, M. A., & Hoppe, R. T. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.1.25 · Cited by 536
Health effects of exposure to low levels of ionizing radiation
Schonken, P. (1991) · Health Policy · doi:10.1016/0168-8510(91)90028-v · Cited by 527
Cancers Complicating Organ Transplantation
Penn, I. (1990) · New England Journal of Medicine · doi:10.1056/nejm199012203232510 · Cited by 512
Leukemia Following Hodgkin's Disease
Kaldor, J. M., Day, N. E., Clarke, E. A., Van Leeuwen, F. E., Henry-Amar, M., Fiorentino, M. V., Bell, J., Pedersen, D., Band, P., Assouline, D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220102 · Cited by 485
Self-citationCancer in the Contralateral Breast after Radiotherapy for Breast Cancer
Boice, J. D., Harvey, E. B., Blettner, M., Stovall, M., & Flannery, J. T. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203193261201 · Cited by 432
Miller, A. B., Howe, G. R., Sherman, G. J., Lindsay, J. P., Yaffe, M. J., Dinner, P. J., Risch, H. A., & Preston, D. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211902 · Cited by 363
Second acute leukemia and other malignancies following treatment for Hodgkin's disease.
Valagussa, P., Santoro, A., Fossati-Bellani, F., Banfi, A., & Bonadonna, G. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.6.830 · Cited by 303
Boice, J. D., Preston, D., Davis, F. G., & Monson, R. R. (1991) · Radiation Research · doi:10.2307/3577890 · Cited by 299
Second cancer risk following testicular cancer: a follow-up study of 1,909 patients.
van Leeuwen, F. E., Stiggelbout, A. M., van den Belt-Dusebout, A. W., Noyon, R., Eliel, M. R., van Kerkhoff, E. H., Delemarre, J. F., & Somers, R. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.415 · Cited by 250
Self-citationSwerdlow, A. J., Douglas, A. J., Hudson, G. V., Hudson, B. V., Bennett, M. H., & MacLennan, K. A. (1992) · BMJ · doi:10.1136/bmj.304.6835.1137 · Cited by 241
RISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE
Pedersen-Bjergaard, J., Olesen Larsen, S., Struck, J., Hansen, H., Specht, L., Ersbøll, J., Hansen, M., & Nissen, N. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92744-9 · Cited by 218
Meadows, A. T., Obringer, A. C., Marrero, O., Oberlin, O., Robison, L., Fossati‐Bellani, F., Green, D., Voǔte, P. A., Morris‐Jones, P., Greenberg, M., et al. (1989) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950170525 · Cited by 165
Andrieu, J., Ifrah, N., Payen, C., Fermanian, J., Coscas, Y., & Flandrin, G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1148 · Cited by 125
Lung cancer following Hodgkin′s disease: A case‐control study
Kaldor, J. M., Day, N., Bell, J., et al. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520502 · Cited by 107
Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study.
Cimino, G. G., Papa, G. F. S., Tura, S., Mazza, P., Ferrini, P. L. R., Bosi, A., Amadori, S., Coco, F. L., D’Arcangelo, E., & Giannarelli, D. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.432 · Cited by 97
Mendenhall, N. P., Shuster, J. J., & Million, R. R. (1989) · Radiotherapy and Oncology · doi:10.1016/0167-8140(89)90170-9 · Cited by 21
Cited by
Miller, T. P., Dahlberg, S., Cassady, J. R., Adelstein, D. J., Spier, C. M., Grogan, T. M., LeBlanc, M., Carlin, S., Chase, E., & Fisher, R. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390104 · Cited by 1,004
Breast Cancer and Other Second Neoplasms after Childhood Hodgkin's Disease
Bhatia, S., Robison, L. L., Oberlin, O., Greenberg, M., Bunin, G., Fossati-Bellani, F., & Meadows, A. T. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341201 · Cited by 905
Late cardiotoxicity after treatment for Hodgkin lymphoma
Aleman, B. M. P., van den Belt-Dusebout, A. W., De Bruin, M. L., van 't Veer, M. B., Baaijens, M. H. A., Boer, J. P. D., Hart, A. A. M., Klokman, W. J., Kuenen, M. A., Ouwens, G. M., et al. (2007) · Blood · doi:10.1182/blood-2006-07-034405 · Cited by 746
Self-citationLong-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease
Aleman, B. M. P., van den Belt-Dusebout, A. W., Klokman, W. J., van’t Veer, M. B., Bartelink, H., & van Leeuwen, F. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.131 · Cited by 716
Self-citationBrice, P., Bastion, Y., Lepage, E., Brousse, N., Haïoun, C., Moreau, P., Straetmans, N., Tilly, H., Tabah, I., & Solal-Céligny, P. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1110 · Cited by 647
Metadata
- Authors
- van Leeuwen, F. E., Klokman, W. J., Hagenbeek, A., Noyon, R., van den Belt-Dusebout, A. W., van Kerkhoff, E. H., van Heerde, P., & Somers, R.
- Venue
- Journal of Clinical Oncology
- Published
- 1994-02
- Volume
- 12
- Issue
- 2
- Pages
- 312-325
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1833833181
- Cited by
- 443
- References
- 25
- FWCI
- 22.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.